ADRX

ADARx Pharmaceuticals Inc

18.25

Oct 02 • 3:59 PM ET -1.29 (-6.60%)

18.38

Aftermarket • 7:30 PM ET +0.13 (0.72%)

Healthcare Biotechnology USA Small NASD

Oct 01, 4:22 PMADARx Pharmaceuticals announces underwriters fully exercise IPO overallotment, increasing offering to 30,187,500 shares and about $513.2 million in gross proceeds

Held by: TMED TDNA TSEE

Index	-
Market Cap	1.87B
Enterprise Value	1.80B
Income	-
Sales	-
Book/sh	-2.35
Cash/sh	4.18
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Sep 25, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	4.37
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	12.98
Current Ratio	12.98
Debt/Eq	0.06
LT Debt/Eq	0.05
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	80.31%
Insider Trans	6.71%
Inst Own	-
Inst Trans	18.51%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-7.05%
SMA50	-7.05%
SMA200	-7.05%
Trades

Shs Outstand	106.80M
Shs Float	20.13M
Short Float	-
Short Ratio	-
Short Interest	-
52W High	23.21 -21.37%
52W Low	18.50 -1.35%
Volatility	11.81% -
ATR (14)	2.55
RSI (14)	-
Beta	-
Rel Volume	0.55
Avg Volume	1.69M
Volume	937,066

Perf Week	-5.68%
Perf Month	-
Perf Quarter	-
Perf Half Y	-
Perf YTD	-17.42%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	19.54
Price	18.25
Change %	-6.60%

Oct-01-26 04:15PM

ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares Granted in Its Initial Public Offering

(GlobeNewswire) -6.60%

ADARx Pharmaceuticals, Inc. is a late-clinical-stage biotechnology company. It focuses on developing next-generation small interfering RNA (siRNA) therapeutics for diseases with significant unmet medical needs. The company was founded by Zhen Li in December 2019 and is headquartered in San Diego, CA.

Co-FounderDr. Zhen Li Ph.D.

Chief Scientific OfficerDr. Robert A. MacLeod Ph.D.

CFO & Chief Business OfficerMr. Ryan Fisk M.B.A.

Ph.D.Dr. Christopher Claeboe M.B.A.

Chief Technology OfficerDr. Rui Zhu Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chimovits Erez	Director	Sep 28 '26	Buy	17.00	61,516	1,045,772	9,292,025	Sep 30 05:29 PM
GORDON CARL L	Director	Sep 28 '26	Buy	17.00	950,000	16,150,000	14,325,529	Sep 30 05:25 PM
ORBIMED ADVISORS LLC	Director	Sep 28 '26	Buy	17.00	950,000	16,150,000	14,325,529	Sep 30 05:23 PM
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	Sep 28 '26	Buy	17.00	1,600,000	27,200,000	5,554,094	Sep 29 09:45 PM
George Simeon	Director	Sep 28 '26	Buy	17.00	1,600,000	27,200,000	5,554,094	Sep 29 09:43 PM

Open in Screener

ODTX

Odyssey Therapeutics Inc

20.73

Oct 02 • 3:59 PM ET +0.31 (1.49%)

20.73

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

ODTX Odyssey Therapeutics Inc daily Stock Chart

Peers: ARVN BBOT XNCR CGEM CTMX JANX KURA ALLO RVMD ROIV

| Held by: VTI IWM VXF IWO SCHA IWN IWC VTWO SCHB RSSL

Index	RUT
Market Cap	996.01M
Enterprise Value	710.26M
Income	-
Sales	-
Book/sh	8.80
Cash/sh	6.46
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	May 08, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.36
P/C	3.21
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	11.36
Current Ratio	11.36
Debt/Eq	0.06
LT Debt/Eq	0.05
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-4.87
EPS next Q	-1.08
EPS this Y	-14.06%
EPS next Y	17.31%
EPS next 5Y	2.20%
EPS past 3/5Y	-6.04% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-41.16%
Sales Q/Q	-100.00%
Earnings	Sep 02
EPS/Sales Surpr.	0.00% -

Insider Own	59.13%
Insider Trans	17.26%
Inst Own	31.44%
Inst Trans	72.82%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-9.96%
SMA50	-8.02%
SMA200	4.05%
Trades

Shs Outstand	47.89M
Shs Float	19.64M
Short Float	11.25%
Short Ratio	8.19
Short Interest	2.21M
52W High	29.05 -28.66%
52W Low	15.10 37.25%
Volatility	8.64% 9.62%
ATR (14)	2.00
RSI (14)	43.18
Beta	-
Rel Volume	0.71
Avg Volume	269.83K
Volume	191,745

Perf Week	1.05%
Perf Month	-22.15%
Perf Quarter	25.83%
Perf Half Y	-
Perf YTD	3.63%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	35.75
Prev Close	20.42
Price	20.73
Change %	1.49%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-27-26	Initiated	H.C. Wainwright	Buy	$44
Jun-02-26	Initiated	Wedbush	Outperform	$30
Jun-02-26	Initiated	TD Cowen	Buy
Jun-02-26	Initiated	Oppenheimer	Outperform	$40
Jun-02-26	Initiated	JP Morgan	Overweight	$26
Jun-02-26	Initiated	Cantor Fitzgerald	Overweight

Sep-16-26 08:00AM	Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum (GlobeNewswire) +5.14%
Aug-26-26 08:00AM	Odyssey Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-07-26 06:10AM	Evotec and Odyssey collaborate on AI-enabled R&D (Pharmaceutical Technology)
Aug-06-26 06:32AM	Odyssey Therapeutics: Q2 Earnings Snapshot (Associated Press)
Aug-04-26 07:00AM	Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) +10.09%
12:56PM	Loading…
Jun-18-26 12:56PM	Kardigan rises in Nasdaq debut after upsized $400 million IPO (Reuters)
Jun-17-26 04:51PM	Odyssey Therapeutics: Q1 Earnings Snapshot (Associated Press)
04:15PM	Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
May-11-26 08:31AM	Healthcare IPOs Raise $4.7 Billion As Odyssey, Mobia Debuts Slip (GuruFocus.com) +6.27%

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company which develops medicines for autoimmune and inflammatory diseases. Its programs include OD-001, an oral small-molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, and OD-002, an oral small-molecule inhibitor of solute carrier family 15 member 4, or SLC15A4. The company was founded by Gary D. Glick, Melissa Merrick and David L. Pompliano in April 2021 and is headquartered in Boston, MA.

FounderDr. Gary D. Glick Ph.D.

Chief Financial OfficerMr. Jason Haas M.B.A.

Senior Vice President of Strategy & Business DevelopmentMr. Collin Todd

Ph.D.Prof. Eicke Latz M.D.

Scientific Co-FounderDr. Kim Lewis Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
TPG GP A, LLC	Former 10% Owner	May 11 '26	Buy	18.00	1,388,889	25,000,002	3,690,146	May 13 05:10 PM
Dimension Capital II, L.P.	Director	May 08 '26	Buy	18.00	1,111,111	19,999,998	3,333,516	May 12 05:37 PM
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	May 11 '26	Buy	18.00	555,555	9,999,990	1,831,383	May 11 09:11 PM
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	May 11 '26	Sale	18.00	1,780	32,040	440,981	May 11 09:11 PM
LEIDEN JEFFREY M	Director	May 08 '26	Buy	20.00	5,000	100,000	270,198	May 11 08:35 PM
Haas Jason	Chief Financial Officer	May 08 '26	Buy	20.00	1,000	20,000	62,908	May 11 08:32 PM
Li Nan (LN)	Director	May 11 '26	Buy	18.00	1,111,111	19,999,998	3,333,516	May 11 08:30 PM
Chu Shelley	Director	May 11 '26	Buy	18.00	11,111	199,998	11,111	May 11 08:30 PM

Open in Screener

AVLN

Avalyn Pharma Inc

28.13

Oct 02 • 3:59 PM ET +0.71 (2.59%)

28.13

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

AVLN Avalyn Pharma Inc daily Stock Chart

Peers: AAPG ABEO SPTX ABCL ABSI AARD ABOS ABVX ACET IVA

| Held by: VTI IWM VXF XPH VTWO IWO SCHA TMSL IHE IWN

Index	RUT
Market Cap	1.25B
Enterprise Value	911.77M
Income	-
Sales	-
Book/sh	8.99
Cash/sh	7.95
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	50
IPO	Apr 30, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	3.13
P/C	3.54
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	33.10
Current Ratio	33.10
Debt/Eq	0.04
LT Debt/Eq	0.04
Option/Short	Yes / Yes

EPS (ttm)	-
EPS next Y	-2.96
EPS next Q	-0.71
EPS this Y	13.10%
EPS next Y	9.65%
EPS next 5Y	7.23%
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Aug 12 BMO
EPS/Sales Surpr.	-26.17% -

Insider Own	39.92%
Insider Trans	8.52%
Inst Own	65.91%
Inst Trans	182.09%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-11.80%
SMA50	-15.54%
SMA200	-8.84%
Trades

Shs Outstand	44.33M
Shs Float	26.64M
Short Float	7.86%
Short Ratio	8.62
Short Interest	2.09M
52W High	40.17 -29.97%
52W Low	24.15 16.48%
Volatility	6.41% 7.28%
ATR (14)	2.17
RSI (14)	36.95
Beta	-
Rel Volume	2.17
Avg Volume	242.76K
Volume	526,199

Perf Week	0.18%
Perf Month	-20.94%
Perf Quarter	1.74%
Perf Half Y	-
Perf YTD	8.19%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.20
Target Price	61.80
Prev Close	27.42
Price	28.13
Change %	2.59%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-02-26	Initiated	Raymond James	Outperform	$60
May-26-26	Initiated	Morgan Stanley	Overweight	$53
May-26-26	Initiated	Jefferies	Buy	$52
May-26-26	Initiated	Guggenheim	Buy	$80
May-26-26	Initiated	Evercore ISI	Outperform	$51

Sep-21-26 09:00AM	Avalyn Publishes Phase 1 Data Highlighting AP02's Lung-Targeted Delivery and Encouraging Safety Profile (GlobeNewswire)
Sep-16-26 04:01PM	Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors (GlobeNewswire)
Sep-08-26 08:00AM	Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference (GlobeNewswire)
08:00AM	Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosis (GlobeNewswire)
Aug-24-26 04:01PM	Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026 (GlobeNewswire)
08:28AM	Loading…
Aug-12-26 08:28AM	Avalyn: Q2 Earnings Snapshot (Associated Press) +5.41%
08:00AM	Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-13-26 09:12AM	What It Means To Hold Moderna Stock In A Crash (Trefis)
Jun-17-26 08:00AM	Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis (GlobeNewswire)
Jun-03-26 08:07AM	Avalyn: Q1 Earnings Snapshot (Associated Press)
07:00AM	Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire)
May-27-26 08:00AM	Avalyn to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-21-26 08:00AM	Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026 (GlobeNewswire)
May-05-26 04:01PM	Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference (GlobeNewswire) -5.64%
May-01-26 04:01PM	Avalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)

Avalyn Pharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). The company was founded by Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar on May 27, 2011 and is headquartered in Boston, MA.

CEOMs. Lyn Baranowski

CFO & Chief Business OfficerMr. Douglas R. Carlson

Ph.D.Dr. Melissa Rhodes DABT

Chief Medical OfficerDr. Howard M. Lazarus M.D.

Senior Director of IR & Corporate CommunicationsMs. Cassie Saitow

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Novo Holdings A/S	10% Owner	May 01 '26	Buy	18.00	555,555	9,999,990	3,883,289	May 05 04:15 PM
Carroll Jill	Director	May 01 '26	Buy	18.00	277,778	5,000,004	2,186,562	May 01 06:50 PM
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	May 01 '26	Buy	18.00	555,555	9,999,990	2,186,562	May 01 06:46 PM

Open in Screener

ZBIO

Zenas Biopharma Inc

28.30

Oct 02 • 3:59 PM ET +0.35 (1.27%)

28.55

Aftermarket • 4:15 PM ET +0.25 (0.90%)

Healthcare Biotechnology USA Small NASD

ZBIO Zenas Biopharma Inc daily Stock Chart

Peers: RYTM KYMR VKTX BMRN CRNX INCY KRYS AXSM MDGL NBIX

| Held by: XBI VTI IWM VXF IWO IBB SCHA VTWO IWC VHT

Index	RUT
Market Cap	1.84B
Enterprise Value	1.59B
Income	-484.38M
Sales	1.00M
Book/sh	3.90
Cash/sh	9.87
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	167
IPO	Sep 13, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	1844.18
P/B	7.25
P/C	2.87
P/FCF	-
EV/EBITDA	-
EV/Sales	1590.65
Quick Ratio	9.93
Current Ratio	9.93
Debt/Eq	1.58
LT Debt/Eq	1.57
Option/Short	Yes / Yes

EPS (ttm)	-9.61
EPS next Y	-5.06
EPS next Q	-1.24
EPS this Y	33.25%
EPS next Y	10.20%
EPS next 5Y	23.61%
EPS past 3/5Y	-39.47% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-127.13%
Sales Y/Y TTM	-93.33%
EPS Q/Q	-41.57%
Sales Q/Q	-
Earnings	Aug 13 BMO
EPS/Sales Surpr.	-57.71% -93.33%

Insider Own	49.20%
Insider Trans	0.38%
Inst Own	74.92%
Inst Trans	22.69%
ROA	-97.39%
ROE	-199.04%
ROIC	-76.18%
Gross Margin	96.90%
Oper. Margin	-27390.10%
Profit Margin	-48438.40%
SMA20	-6.81%
SMA50	-9.38%
SMA200	11.94%
Trades

Shs Outstand	63.33M
Shs Float	33.11M
Short Float	35.85%
Short Ratio	16.09
Short Interest	11.87M
52W High	44.60 -36.56%
52W Low	13.50 109.59%
Volatility	6.82% 6.36%
ATR (14)	1.96
RSI (14)	41.86
Beta	-0.87
Rel Volume	2.05
Avg Volume	737.66K
Volume	1,513,616

Perf Week	4.99%
Perf Month	-14.59%
Perf Quarter	6.98%
Perf Half Y	31.85%
Perf YTD	-22.07%
Perf Year	35.06%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.25
Target Price	47.88
Prev Close	27.94
Price	28.30
Change %	1.27%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-05-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$19
Mar-20-25	Initiated	Wedbush	Outperform	$35
Feb-04-25	Initiated	Wolfe Research	Outperform	$19
Dec-16-24	Initiated	H.C. Wainwright	Buy	$30
Nov-05-24	Initiated	Rodman & Renshaw	Buy	$34
Oct-08-24	Initiated	Morgan Stanley	Overweight	$40
Oct-08-24	Initiated	Jefferies	Buy	$35
Oct-08-24	Initiated	Guggenheim	Buy	$45
Oct-08-24	Initiated	Citigroup	Buy	$27

Sep-22-26 07:05AM	Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026 (GlobeNewswire)
Sep-18-26 04:15PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-08-26 07:05AM	Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event (GlobeNewswire)
Sep-04-26 07:05AM	Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences (GlobeNewswire)
Aug-28-26 07:46PM	Fortune Brands and 4 More Stocks See Action From Activist Investors (Barrons.com)
04:15PM	Loading…
Aug-18-26 04:15PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-13-26 07:00AM	Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) -6.68%
Jul-17-26 04:15PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-17-26 04:15PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.46%
Jun-11-26 04:15PM	Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit (GlobeNewswire) +11.49%
Jun-02-26 07:05PM	Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine (GlobeNewswire) -5.72%
May-28-26 07:05AM	Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD (GlobeNewswire)
May-19-26 07:05AM	Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress (GlobeNewswire) +5.50%
May-18-26 04:15PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.80%
May-13-26 06:50AM	Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor (GlobeNewswire)
06:00AM	Loading…
06:00AM	Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-17-26 04:15PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-27-26 12:12AM	Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million (GlobeNewswire) -17.82%
Mar-26-26 04:01PM	Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock (GlobeNewswire)
Mar-16-26 06:01PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-28-26 10:56AM	Zenas BioPharma, Inc. (ZBIO): A Bull Case Theory (Insider Monkey)
Feb-20-26 04:15PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-19-26 07:09AM	Encouraging Phase II Trial Data Supported Zenas BioPharma, Inc. (ZBIO) in Q4 (Insider Monkey)
Feb-16-26 04:07AM	Zenas BioPharma Highlights Obexelimab Phase 3 Win, Targets Q2 BLA Filing at Guggenheim Summit (MarketBeat)
Feb-09-26 07:05AM	Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026 (GlobeNewswire)
Feb-04-26 07:05AM	Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Jan-16-26 04:15PM	Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-10-26 09:01AM	Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet (Benzinga)
Jan-07-26 06:46AM	Zenas BioPharma Touts Phase 3 Win, But Stock Crashes (Benzinga) +8.62%
11:18AM	Loading…
Jan-06-26 11:18AM	ZBIO Tanks Despite Positive Data From Rare Autoimmune Diseases Study (Zacks) -8.49%
06:25AM	Zenas stock drops 51% despite lead assets Phase III rare disease win (Clinical Trials Arena)
Jan-05-26 04:23PM	Zenas BioPharma, A Top 1% Stock, Quadrupled In 2025. Why It Just Collapsed. (Investor's Business Daily) -51.86%
07:05AM	Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) (GlobeNewswire)
06:26AM	Zenas shares crash after top drug misses expectations in immune disease study (BioPharma Dive)
Dec-19-25 04:15PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +17.10%
Dec-15-25 07:05AM	Zenas BioPharma's Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus (GlobeNewswire) -19.71%
Dec-12-25 09:45AM	Huge Insider Buying in MGM and Salesforce (24/7 Wall St.)
Dec-03-25 07:25AM	Meridian Small Cap Growth Fund Trimmed Zenas BioPharma (ZBIO) Following Share Price Appreciation (Insider Monkey) +6.29%
Nov-12-25 07:05AM	Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-11-25 07:05AM	Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences (GlobeNewswire) +8.41%
Oct-31-25 12:41PM	How Royalty Pharma Prints Cash Without Biotech's Biggest Risks (MarketBeat)
Oct-28-25 01:34PM	1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data (MarketBeat) -5.06%
08:35AM	Zenas bifunctional mAb scores at Phase II in relapsing MS (Clinical Trials Arena)
06:00AM	Incyte trims pipeline; Zenas surges on MS drug results (BioPharma Dive)
Oct-27-25 07:05AM	Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis (GlobeNewswire) +33.08%
Oct-08-25 05:00AM	Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis (GlobeNewswire) +24.22%
Sep-02-25 07:05AM	Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million (GlobeNewswire) +9.50%
Aug-26-25 07:05AM	Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences (GlobeNewswire)
Aug-12-25 07:05AM	Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire) +6.68%
Jun-20-25 04:15PM	Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-13-25 05:45AM	Zenas BioPharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ZBIO (PR Newswire) -8.75%
Jun-02-25 04:00AM	ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO (PR Newswire) +5.67%
May-29-25 07:05AM	Zenas BioPharma to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) +8.34%
May-28-25 09:31AM	ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO (PR Newswire) -12.59%
May-16-25 05:45AM	Investors in Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO (PR Newswire) +7.49%
May-15-25 07:05AM	Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire) +12.21%
May-06-25 05:45AM	Zenas BioPharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ZBIO (PR Newswire) -19.71%
May-02-25 05:45AM	Shareholders of Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO (PR Newswire)
Apr-29-25 05:45AM	Zenas BioPharma, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO (PR Newswire) +12.56%
Apr-22-25 10:37AM	Cohen Milstein Calls on Zenas BioPharma (ZBIO) Investors to Act Following Significant Post-IPO Losses (GlobeNewswire)
Apr-21-25 12:33PM	Zenas Biopharma Investors Urged to Contact Cohen Milstein After Post-IPO Losses (GlobeNewswire) +9.30%
Apr-17-25 04:20PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.08%
Apr-07-25 03:08PM	Zenas: Differentiated B-Cell Targeting Drug With Q3 Of 2025 Catalyst (Seeking Alpha)
07:05AM	Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer (GlobeNewswire)
Mar-20-25 02:54PM	Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress (Benzinga)
11:41AM	Zenas Bio rises as Wedbush launches with Outperform on lead asset (SeekingAlpha)
Mar-17-25 07:05AM	Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer (GlobeNewswire)
Feb-05-25 07:05AM	Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases (GlobeNewswire)
Jan-28-25 08:00AM	Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Dec-17-24 06:25AM	Zenas BioPharma initiated with a Buy at H.C. Wainwright (TipRanks) +8.10%
Dec-12-24 07:35AM	Zenas BioPharma price target lowered to $35 from $40 at Morgan Stanley (TipRanks)
Nov-12-24 07:10AM	Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
07:05AM	Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) (GlobeNewswire)
Nov-07-24 07:05AM	Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences (GlobeNewswire)
Oct-14-24 06:45AM	Opening Day: Another trio of biotech IPOs make Friday debut (TipRanks) +7.63%
Sep-19-24 04:15PM	Zenas BioPharma Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering (GlobeNewswire) +8.45%
Sep-13-24 04:09PM	Biotech IPO Shares Climb in Debuts After Deals Upsized (Bloomberg)
12:19AM	Bicara Leads Trio of US Biotech IPOs Raising $703 Million (Bloomberg)
Sep-12-24 10:37PM	Zenas BioPharma Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

M.B.A.Mr. Leon Oliver Moulder Jr.

COO & PresidentMr. Joseph L. Farmer

Head of Research & Development and Chief Medical OfficerDr. Lisa von Moltke M.D.

Chief Business Officer & CFOMs. Jennifer A. Fox

Chief Technical OfficerDr. Heinrich Schlieker Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zebra Aggregator, LP	Affiliate	Aug 19 '26	Proposed Sale	31.91	1,000,000	31,910,000		Aug 19 04:15 PM
MOULDER LEON O JR	Chief Executive Officer	May 18 '26	Buy	16.88	60,000	1,012,800	96,928	May 18 09:12 PM
MOULDER LEON O JR	Chief Executive Officer	Apr 29 '26	Buy	17.62	35,000	616,700	1,786,039	Apr 29 07:21 PM
MOULDER LEON O JR	Chief Executive Officer	Apr 28 '26	Buy	18.02	25,000	450,500	1,751,039	Apr 29 07:21 PM
Lu Hongbo	Director	Mar 31 '26	Buy	18.63	3,768	70,198	426,736	Apr 02 05:02 PM
Fairmount Funds Management LLC	Director	Mar 31 '26	Buy	20.00	150,000	3,000,000	2,359,025	Apr 01 04:30 PM
MOULDER LEON O JR	Chief Executive Officer	Mar 31 '26	Buy	19.31	34,000	656,540	1,726,039	Mar 31 08:14 PM
MOULDER LEON O JR	Chief Executive Officer	Mar 30 '26	Buy	18.23	20,000	364,600	1,692,039	Mar 31 08:14 PM
Lu Hongbo	Director	Mar 31 '26	Buy	20.00	75,000	1,500,000	422,968	Mar 31 05:00 PM
Lu Hongbo	Director	Feb 11 '26	Buy	22.50	25,985	584,662	347,968	Feb 13 05:35 PM
Allen Patricia L	Director	Feb 12 '26	Buy	24.85	15,700	390,088	15,700	Feb 13 05:06 PM
Allen Patricia L	Director	Feb 13 '26	Buy	26.36	4,160	109,658	19,860	Feb 13 05:06 PM
MOULDER LEON O JR	Chief Executive Officer	Feb 02 '26	Buy	17.96	57,000	1,023,720	423,155	Feb 03 04:30 PM
MOULDER LEON O JR	Chief Executive Officer	Jan 07 '26	Buy	16.38	50,000	819,000	316,155	Jan 09 09:42 PM
MOULDER LEON O JR	Chief Executive Officer	Jan 08 '26	Buy	16.30	30,000	489,000	346,155	Jan 09 09:42 PM
MOULDER LEON O JR	Chief Executive Officer	Jan 09 '26	Buy	16.55	20,000	331,000	366,155	Jan 09 09:42 PM
Nunn Jason Raleigh	Director	Oct 09 '25	Buy	19.00	63,158	1,200,002	1,173,395	Oct 14 05:16 PM
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	Oct 09 '25	Buy	19.00	126,315	2,399,985	1,917,895	Oct 14 05:14 PM
ENRIGHT PATRICK G	Director	Oct 09 '25	Buy	19.00	105,265	2,000,035	1,832,669	Oct 14 08:59 AM
ENRIGHT PATRICK G	Director	Oct 09 '25	Buy	20.85	11,990	249,992	11,990	Oct 14 08:59 AM
MOULDER LEON O JR	See Remarks	Oct 07 '25	Buy	20.85	36,928	769,949	36,928	Oct 09 05:24 PM
Fairmount Funds Management LLC	Director	Oct 07 '25	Buy	19.00	316,219	6,008,161	2,209,025	Oct 09 04:15 PM
Lu Hongbo	Director	Oct 07 '25	Buy	19.00	263,160	5,000,040	321,983	Oct 09 03:37 PM

ADRX

ADARx Pharmaceuticals Inc

ODTX

Odyssey Therapeutics Inc

AVLN

Avalyn Pharma Inc

ZBIO

Zenas Biopharma Inc

Upgrade your Finviz experience